¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple system atrophy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® lymphatic system ÇÑ±Û ¸²ÇÁ°è
¼³¸í   
  ´ë°³ ¸Æ°ü°è¶ó°í Çϸé, Ç÷°ü°è¿Í ¸²ÇÁ°ü°è¸¦ ÇÕÃļ­ ¸»ÇÑ´Ù. ÀÌÁß¿¡ ¸²ÇÁ¿¡ ÀÇÇØ ÀÌ·ç¾îÁö´Â ÇϳªÀÇ °èÅëÀÌ´Ù.
¿µ¹® immune system ÇÑ±Û ¸é¿ªÃ¼°è
¼³¸í   
  ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼­, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇϴ °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀΠ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀΠºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù.
  
  
¿µ¹® urinary system ÇÑ±Û ºñ´¢±â°èÅë
¼³¸í   
  ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼­ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼­, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇ졒ʡÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù.
  
  ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼­ Çü¼ºµÈ ¿ÀÁܴ ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼­ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù.
¿µ¹® reproductive system ÇÑ±Û »ý½Ä±â°èÅë
¼³¸í   
  1.³²¼º»ý½Ä°èÅë: ³²¼º»ý½Ä±â´Â Á¤ÀÚ(sperm)¸¦ »ý¼ºÇϴ °íȯ°ú Á¤ÀÚÀÇ ¼º¼÷, ¿î¹Ý, ±×¸®°í »çÁ¤¿¡ °ü¿©Çϴ ºÎ°íȯ, Á¤°ü, À½°æ(penis) µîÀ¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç, ºÎ¼Ó±â°üÀ¸·Î ¿ÜºÐºñ»ùÀΠÁ¤³¶(seminal vesicle), Àü¸³»ù(prostate), ¿äµµ¸Á¹°»ù(bulbourethral gland, Cowper¡¯s gland) µîÀ» °®Ãß°í ÀÖ´Ù. °íȯÀº Á¤ÀÚ¸¦ »ý»êÇϴ »ý½Ä»ùÀΠµ¿½Ã¿¡ ³²¼ºÈ£¸£¸ó(testosterone)À» ºÐºñÇϴ ³»ºÐºñ»ùÀÌ´Ù. °íȯ¿¡¼­ ºÐºñµÇ´Â ³²¼ºÈ£¸£¸óÀº Á¤ÀÚ»ý¼º°ú »ý½Ä±âÀÇ ¹ß´Þ ¹× À¯Áö¿¡ ÇʼöÀûÀΠ¿ªÇÒÀ» ÇϹǷΠ³²¼º»ý½Ä±â´ÉÀÇ ¿øÃµÀº °íȯ¿¡ ÀÖ´Ù°í º¼ ¼ö ÀÖ´Ù.
  
  2.¿©¼º»ý½Ä°èÅë: ¿©¼º»ý½Ä±â´Â ³­ÀÚ¸¦ »ý¼ºÇϴ ³­¼Ò¿Í ³­ÀÚ¸¦ ÀÚ±ÃÀ¸·Î ¿î¹ÝÇϴ ³­°ü, ±×¸®°í Àڱðú Áú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¿ÜºÐºñ¼±ÀΠ¹Ù¸£Å縰»ù¸¦ °®Ãß°í ÀÖ´Ù. ³­¼Ò´Â ³­ÀÚ¸¦ »ý¼ºÇϴ »ý½Ä»ùÀΠµ¿½Ã¿¡ ¿©¼ºÈ£¸£¸óÀ» ºÐºñÄÉÇϴ ³»ºÐºñ»ùÀÌ´Ù. ¿ù°æÁÖ±â Àü¹ÝºÎ¿¡ ³­ÀÚ¸¦ »ý¼º½Ã۱âÀ§ÇØ ¼º¼÷µÇ°í Àִ ³­Æ÷¿¡¼­ ºÐºñµÇ´Â ¿¡½ºÆ®·Î°ÕÀº ¿©¼º 2Â÷ ¼ºÂ¡ÀÇ ¹ß´ÞÀ» °üÀåÇÒ »Ó ¾Æ´Ï¶ó Àڱ󻸷À» ÀåÂ÷ ¼öÁ¤µÉ ¼öÁ¤¶õÀÌ Âø»óÇϱ⿡ ¾Ë¸ÂÀº »óÅ·Π¸¸µé¾îÁØ´Ù. ³­ÀÚ°¡ ºÐºñµÇ°í ³²Àº È²Ã¼¿¡¼­ ºÐºñµÇ´Â Çª·Î°Ô½ºÅ×·ÐÀº Àڱ󻸷À» º×µµ·Ï Çϸ頺кñ¾×À» Áõ°¡½Ã۸ç ÀڱñÙÀÇ ¼öÃàÀ» ¹æÇØÇÏ¿© ÀӽŽàÀÓ½ÅÀ» Áö¼Ó½Ã۴ ¿ªÇÒÀ» ÇÑ´Ù.
¿µ¹® digestive system ÇÑ±Û ¼ÒÈ­±â°èÅë
¼³¸í   
  ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ­, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼­ ºÎ¸£´Â ¸».
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • steroid-induced atrophy
    ½ºÅ×·ÎÀ̵åÀ¯¹ßÀ§Ãà
  • subcutaneous atrophy
    ÇǺιØÀ§Ãà, ÇÇÇÏÀ§Ãà
  • senile atrophy
    ³ë³âÀ§Ãà
  • serous atrophy
    Àå¾×¼ºÀ§Ãà
  • simple atrophy
    ´Ü¼øÀ§Ãà
  • villous atrophy
    À¶¸ðÀ§Ãà
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ, À¯Àü´Ù¹ß¿Ü°ñÁõ
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù¼ö-, ´ÙÁß-, ´Ù-
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶À¯ÀüÀÚ, º¹¼ö´ë¸³À¯ÀüÀÚ
  • multiple birth
    ´Ùžƺи¸
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • serous atrophy
    Àå¾×À§Ãà
  • simple atrophy
    ´Ü¼øÀ§Ãà
  • spinal muscular atrophy
    ô¼ö±ÙÀ°À§Ãà
  • steroid-induced atrophy
    ½ºÅ×·ÎÀ̵åÀ§Ãà
  • subcutaneous atrophy
    ÇÇÇÏÀ§Ãà, ÇǺιØÀ§Ãà
  • toxic atrophy
    Áßµ¶À§Ãà
  • villous atrophy
    À¶¸ðÀ§Ãà
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶ÀÎÀÚ
  • multiple endocrine adenomatosis
    ´Ù¹ß³»ºÐºñ»ùÁ¾Áõ
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê, °æ»ê
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple deformity
    º¹ÇÕ±âÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • postinflammatory optic atrophy
    ¿°ÁõÈĽýŰæÀ§Ãà
  • postneuritic optic atrophy
    ¿°ÁõÈĽýŰæÀ§Ãà
  • pressure atrophy
    ¾Ð¹ÚÀ§Ãà(äâÚÞê×õê).
  • primary optic atrophy
    ¿ø¹ß½Ã½Å°æÀ§Ãà(ê«Û¡ãÊãêÌèê×õê).
  • primary optic atrophy
    ¿ø¹ß(¼º) ½Ã½Å°æÀ§Ãà(ê«Û¡(àõ) ãÊãêÌèê×õê)
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(¡­ãêÌèàõÐÉê×õê).
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(òäú¼àõ ãêÌèàõ ÐÉê×õê)
  • progressive unilateral facial atrophy
    ÁøÇ༺ Æí¾È¸éÀ§Ãà(òäú¼àõø¸äÔØüê×õê ).
  • progressive unilateral facial atrophy
    ÁøÇ༺ Æí¾È¸éÀ§Ãà(òäú¼àõ ø¸äÔØüê×õê )
  • red atrophy
    Àû»öÀ§Ãà(îåßäê×õê)
  • renal atrophy
    ½ÅÀ§Ãà(ãìê×õê).
  • renal atrophy
    ½ÅÀ§Ãà(ãìê×õê)
  • renal atrophy
    ½ÅÀ§Ãà
  • ABH system
    ABH °è(Åë)
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • dentate cerebellar atrophy
    ½Å¿ÜÄ¡»óÇÙ¼Ò³úÀ§Ãà(öÍßÒú·á³Òàê×õê).
  • diffuse atrophy of alveolar bone
    ¹Ì¸¸¼º Ä¡Á¶°ñÀ§Ãà(¡­öÍðËÍéê×õê).
  • diffuse cerebral atrophy
    ¹Ì¸¸¼º ³úÀ§Ãà.
  • disuse atrophy
    ¹«¿ë¼º À§Ãà(ÙíéÄàõê×õê), ¹«À§À§Ãà, ºÎµ¿ÀÛ¼º À§Ãà.
  • disuse atrophy
    ºÒ¿ë¼º À§Ãà(ÝÕéÄàõê×õê), ¹«¿ë¼º À§Ãà(ÙíéÄàõê×õê), ¹«À§ À§Ãà, ºÎµ¿ÀÛ¼º À§Ãà.
  • eccentric atrophy
    Æí½É¼º À§Ãà(ø¶ãýàõê×õê), ¿ø½É¼º À§Ãà(¡­ê×õê).
  • eccentric atrophy
    ¿ø½É¼º À§Ãà(¡­ê×õê).
  • electric optic atrophy
    Àü±â½Ã½Å°æÀ§Ãà
  • endometrium,senile cystic atrophy
    ³ëÀμº ³¶¼º À§Ãà
  • essential iris atrophy
    º»Å¼ºÈ«Ã¤À§Ãà, Ư¹ß¼ºÈ«Ã¤À§Ãà
  • facial atrophy
    ¾È¸éÀ§Ãà
  • facioscapulohumeral atrophy
    ¾È¸é°ß°©»ó¿Ï(±Ù)À§Ãà(Áõ)(¡­Ì·Ë£ß¾èÓÐÉê×õêñø).
  • familial spinal muscular atrophy
    °¡Á·¼º ô¼ö¼º ±ÙÀ§Ãà(Áõ).
  • fat atrophy
    Áö¹æ À§Ãà
  • gastric atrophy
    À§¼±À§Ãà(êÖàÍê×õê).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • extrinsic system
    ¿ÜÀÎ(èâì×) ½Ã½ºÅÛ
  • FAS system
    FAS ½Ã½ºÅÛ
  • fatty acid synthetase system
    Áö¹æ»ê ÇÕ¼º È¿¼Ò(ò·Û¸ß«ùêà÷ý£áÈ)½Ã½ºÅÛ
  • genetic system
    À¯Àü(ë¶îî) ½Ã½ºÅÛ
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • hydrogen transport system
    ¼ö¼Ò ¼ö¼Û(â©áÈâÃáê) ½Ã½ºÅÛ
  • inducible system
    À¯µµ°¡´É(ë¯ÓôʦÒö) ½Ã½ºÅÛ
  • intrinsic system
    ³»ÀÎ(Ò®ì×) ½Ã½ºÅÛ
  • isolated system
    °Ý¸®(̰×î)½Ã½ºÅÛ
  • Kovats retention index system
    ÄÚ¹ÙÆ® ü·ù(ôò׺) Áö¼ö(ò¦â¦)½Ã½ºÅÛ
  • K system
    K ½Ã½ºÅÛ
  • leiotonin system
    ¶óÀÌ¿ÀÅä´Ñ ½Ã½ºÅÛ
  • MN blood group system
    MN½Ä(ãÒ)Ç÷¾×Çü(úìäûúþ)
  • model system
    ¸ðµ¨½Ã½ºÅÛ
  • multienzyme system
    ´ÙÈ¿¼Ò(Òýý£áÈ)½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • electronically steered system
    ÀüÀÚÁ¶ÇâÀåÄ¡
  • hospital information system(HIS)
    º´¿øÁ¤º¸È­Ã¼°è
  • lymphatic system
    ¸²ÇÁ°è
  • OCS(order communication system)
    ó¹æÀü´Þü°è
  • operating system [=OS]
    ¿î¿µÃ¼°è
  • OS [=operating system]
    ¿î¿µÃ¼Á¦
  • PACS [=picture archiving and communicating system]
    ÆÑ½º, ¿µ»óÀúÀå ¹× Àü¼Ûü°è
  • portal system
    ¹®¸Æ°è
  • radiologic information system(RIS)
    ¹æ»ç¼±°ú Á¤º¸È­Ã¼°è
  • real time system
    ½Ç½Ã°£Ã¼°è
  • reproductive system
    »ý½Ä±â°èÅë
  • reticuloendothelial system
    ¼¼¸Á³»Çǰè, ¸Á³»°è
  • urinary system
    ºñ´¢±â°è
  • vegetative nervous system
    ÀÚÀ²½Å°æ°è
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MODS medically oriented data system; multiple-organ dysfunction syndrome
MOSF multiple organ system failure
MSD material safety data; mean square deviation; mild sickle cell disease; most significant digit; multi...
MSS Marshall-Smith syndrome; massage; Medical Superintendents' Society; Medicare Statistical System; men...
TMS thalium myocardial scintigraphy; thread mate system; thymidilate synthase; trapezoidocephaly-multipl...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HCSMA Hereditary Canine Spinal Muscular Atrophy
HA Hippocampal atrophy
OPCA Olivo-Ponto-Cerebellar Atrophy
PMA Peroneal muscular atrophy
PCA Posterior Cortical Atrophy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • reticular atrophy
    ¸Á»ó À§Ãà
  • senile atrophy
    ³ë³â¼º À§Ãà, ³ëÀμº À§Ãà
    ³ªÀ̰¡ µê¿¡ µû¸¥ ¸ðµç Á¶Á÷ÀÇ »ý¸®ÀûÀÎ À§Ãà.
  • spinal progressive muscular atrophy
    ô¼ö¼º ÁøÇ༺ ±ÙÀ§ÃàÁõ
    ô¼ö ¹× ¿¬¼öÀÇ ¿îµ¿ ½Å°æ ¼¼Æ÷ÀÇ º¯¼º¿¡ ÀÇÇÏ¿© Àü½ÅÀÇ ±ÙÀ§Ãà°ú Å»·ÂÀ» ÀÏÀ¸Å°´Â º´. ¼Õ, ¹ßÀÇ ±ÙÀ° À§Ãà¿¡¼­ ½ÃÀÛÇÏ¿© Á¡Â÷·Î »óÇàÇØ¼­ ¸ñÀÇ ±ÙÀ°°ú ¸öÅëÀÇ ±ÙÀ°µµ Ä§ÇØµÈ´Ù. »ó, ÇÏÁöÀÇ ÈûÁٹݻ簡 ¾àÇØÁö°í ¹Ùºó½ºÅ° ¹Ý»ç´Â À½¼ºÀÌ µÈ´Ù. °æ°ú°¡ ±æ°í Á¶±â¿¡ »ç¸ÁÇÏ´Â ÀÏÀº ¾øÀ¸³ª, °«³­¾Æ±â¿¡¼­ º¼ ¼ö ÀÖ´Â ÀÌ º´À» º£¸£Æ®´ÏÈ÷-È£ÇÁ¸¸ º´À̶ó°í Çϸç, ¼ö³â À̳»¿¡ »ç¸ÁÇÑ´Ù. ¶Ç À̰Ͱú ±Ù¿¬°ü°è¿¡ ÀÖ´Â °¡Á·¼º ô¼ö¼º ±ÙÀ§¼º ±Ù À§ÃàÁõµµ ÀÌ º´ÀÇ ÇÑ ÇüÀÌ´Ù. 3¼¼ ÀÌÈÄÀÇ ¾î´À ¿¬·ÉÃþ¿¡¼­³ª ¹ßº´ÇÏ¸ç ±ä °æ°ú¸¦ ÃëÇÑ´Ù. Ư¼öÇÑ Ä¡·á¹ýÀº ¾ø°í ¿îµ¿ ¿ä¹ýÀÌ ÇÊ¿äÇÏ´Ù.
  • Zimmerlin's atrophy
    Áü¸Þ¸¦¸° À§Ãà
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • multiple
    ´Ù¹ß¼º, ´Ù¼öÀÇ
  • multiple abutment
    ´Ù¼ö Áö´ëÄ¡
  • multiple allelomorph
    º¹´ë¸³ À¯ÀüÀÚ
  • multiple anchorage
    º¹ÇÕ °íÁ¤
    1Çü½Ä ÀÌ»óÀÇ ÈûÀ» °¡ÇÏ´Â ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °íÁ¤.
  • multiple angioma
    ´Ù¹ß¼º ¸Æ°üÁ¾
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • multiple cavernous hemangioma
    ´Ù¹ß¼º ÇØ¸é Ç÷°üÁ¾
  • multiple condylome
    ´Ù¹ß¼º ½À¿ì
  • multiple cranial nerve palsy
    ´Ù¹ß¼º ³ú ½Å°æ ¸¶ºñ
  • multiple diagnosis
    º¹¼ö Áø´Ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
multiple fracture Fracture at two or more places in a bone.
See: segmental fracture.
Fracture of several bones occurring simultaneously.
(05 Mar 2000)
multiple gestation <radiology> Incidence: 1% of all births, twins in 1:85; triplets in 1:85x85; etc, uterus large for dates, may have elevated hCG, hPL, and aFP, at risk for IUGR: monochorionic-monoamniotic more than , monochorionic-diamniotic more than , dichorionic-diamniotic findings: 2 placentas indicate dichorionic-diamniotic, 1 placenta indicates monochorionic pregnancy or dichorionic pregnancy with fused placenta, separating membranes confirms diamniotic pregnancy
(12 Dec 1998)
multiple glandular deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple hamartoma syndrome Hypertrichosis and gingival fibromatosis from infancy, accompanied by postpubertal fibroadenomatous breast enlargement; papules of the face are characteristic of multiple trichilemmomas.
Synonym: multiple hamartoma syndrome.
(05 Mar 2000)
multiple idiopathic haemorrhagic sarcoma <oncology, tumour> A type of vascular cancer characterised by soft purple nodules that usually develop first on the feet and then slowly spread across the skin.This cancer is most often found in people with compromised immune systems, such as AIDS patients.
(09 Oct 1997)
multiple infection <epidemiology> An infection in which an individual is infected by parasites of more than one species.
(05 Dec 1998)
multiple intestinal polyposis Begins usually in late childhood; polyps increase in numbers, causing symptoms of chronic colitis, and carcinoma of the colon almost invariably develops in untreated cases; autosomal dominant inheritance. In the Gardner syndrome there are extracolonic changes (desmoid tumours, etc.).
Synonym: polyposis coli.
Hamartomatous polyposis of the small or large intestine, Peutz-Jeghers syndrome with melanin spots on the lips, less common, miscellaneous, rare, and doubtful occurrences.
Synonym: familial intestinal polyposis.
(05 Mar 2000)
multiple lentigines syndrome <syndrome> An autosomal dominant inherited disorder characterised by freckle-like spots (lentigines) on the trunk. Other findings may include wide set eyes, sternum abnormalities, prominent ears, deafness, cafe-au-lait spots, pulmonary stenosis, cryptorchidism, delayed puberty or hypogonadism. There is no treatment available only underlying management of each problem.
Inheritance: autosomal dominant.
(27 Sep 1997)
multiple lipoprotein-type hyperlipidaemia <biochemistry> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides. There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease.
Origin: Gr. Haima = blood
(27 Sep 1997)
multiple mucosal neuroma syndrome <syndrome> Multiple submucosal neuromas or neurofibromas of the tongue, lips, and eyelids in young persons; sometimes associated with tumours of the thyroid or adrenal medulla, or with subcutaneous neurofibromatosis.
(05 Mar 2000)
multiple myeloma <oncology, tumour> See myeloma cell.
(18 Nov 1997)
multiple myelomatosis <oncology, tumour> See myeloma cell.
(18 Nov 1997)
multiple myositis The occurrence of multiple foci of acute inflammation in the muscular tissue and overlying skin in various parts of the body, accompanied by fever and other signs of systemic infection.
See: dermatomyositis.
Synonym: acute disseminated myositis, pseudotrichinosis, pseudotrichiniasis.
(05 Mar 2000)
multiple neuritis <neurology> A disease process involving a number of peripheral nerves.
Origin: Gr. Pathos = disease
(14 Oct 1997)
multiple organ failure A progressive condition usually characterised by combined failure of the lungs, liver, kidney, and clotting mechanisms, usually postinjury or postoperative.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • central nervous system
    ÁßÃß ½Å°æ°è
  • chit system
    ÀüÇ¥ ÁöºÒÁ¦
  • circulatory system
    ¼øÈ¯°è(Ç÷¾×À̳ª ¸²ÇÁ¾×ÀÌ È帣°Ô ÇÏ´Â)
  • closed ecological system
    »ýÅÂÇÐÀû Æó¼â°è
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • container system
    ÄÁÅ×ÀÌ³Ê ¼ö¼Û¹æ½Ä
  • convict system
    ¡¿ª(À¯Çü)Á¦µµ
  • coupon system
    °æÇ°ºÎ ÆÇ¸Å¹ý
  • data base management system
    (Àü»ê)µ¥ÀÌÅͺ£À̽º °ü¸® ½Ã½ºÅÛ(¾à DBMS)
  • decimal system
    ½ÊÁø¹ý
  • decision support system
    (Àü»ê)(°æ¿µÀÇ)ÀÇ»ç °áÁ¤ Áö¿ø ½Ã½ºÅÛ
  • delayed time system
    (ÀüÀÚ)½Ã°£ Áö¿¬(ÃàÀû)¹æ½Ä
  • digestive system
    (ÇØ)¼ÒÈ­±â °èÅë(ÀÔ,À§,Àå µî)
  • domestic system
    °¡³» °ø¾÷ Á¦µµ
  • duples system
    (Àü»ê)º¹½Ä ½Ã½ºÅÛ(2´ëÀÇ ÄÄÇ»Å͸¦ ¼³Ä¡Ç쵂 Çϳª´Â ¿¹ºñ¿ë)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á